Cargando…

Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study

BACKGROUND: So far the prevalence of viral hepatitis infection in hospitalized patients has not been extensively studied. Therefore we conducted the present five-year observational study to evaluate the prevalence of HBV and HCV infection in high-risk hospitalized patients of Crete, the largest Gree...

Descripción completa

Detalles Bibliográficos
Autores principales: Koulentaki, Meri, Ergazaki, Maria, Moschandrea, Joanna, Spanoudakis, Stelios, Tzagarakis, Nikolaos, Drandakis, Pandelis E, Spandidos, Dimitrios A, Kouroumalis, Elias A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64645/
https://www.ncbi.nlm.nih.gov/pubmed/11806759
http://dx.doi.org/10.1186/1471-2458-1-17
_version_ 1782120138781229056
author Koulentaki, Meri
Ergazaki, Maria
Moschandrea, Joanna
Spanoudakis, Stelios
Tzagarakis, Nikolaos
Drandakis, Pandelis E
Spandidos, Dimitrios A
Kouroumalis, Elias A
author_facet Koulentaki, Meri
Ergazaki, Maria
Moschandrea, Joanna
Spanoudakis, Stelios
Tzagarakis, Nikolaos
Drandakis, Pandelis E
Spandidos, Dimitrios A
Kouroumalis, Elias A
author_sort Koulentaki, Meri
collection PubMed
description BACKGROUND: So far the prevalence of viral hepatitis infection in hospitalized patients has not been extensively studied. Therefore we conducted the present five-year observational study to evaluate the prevalence of HBV and HCV infection in high-risk hospitalized patients of Crete, the largest Greek island, Due to the homogeneous population, epidemiological studies can be accurately done. METHODS: The study was carried out in two out of four District General Hospitals, and in the University Hospital of the island. Markers for HBV and HCV were studied and statistically evaluated according to age, sex and geographical area, in a well-defined hospitalized population. RESULTS: The total prevalence of HBsAg and anti-HCV in the three prefectures during the five-year study is 2.66% and 4.75% respectively. Overall the relative risks were higher in males than females for each hepatitis marker (p < 0.001). Higher prevalence of HBcAb was found in the 41–60 years age group for both sexes (males 36.17%, females 27.38%). Peak HBsAg prevalence was found in the age group of 21–40 and 41–60 years for males (5.4%) and females (3.09%) respectively. Anti-HCV prevalence increases with age reaching the highest prevalence in the age group of 41–60 years for males (7.19%) and in the 61–90 years age group for females (7.16%). For both sexes significant differences between the three locations were identified. For HBsAg a higher prevalence in Heraklion (3.96%) compared to Chania (2.30%, males: p < 0.0001, females: p < 0.05) and Rethymnon (1.45%, males: p < 0.01, females: p < 0.0001) was detected. For HCV a significantly higher prevalence in Heraklion (6.54%) compared to Chania (2.39%, males: p < 0.001, females: p < 0.001) but not in Rethymnon (5.15%, NS). A lower prevalence rate of HBcAb in Heraklion compared to Chania (20.07% versus 23.05%, males: p < 0.001, females: p < 0.001) was found. CONCLUSIONS: These results were possibly overestimated, but nevertheless reflect the situation of the general population within the island as shown by our previous publications in other study groups. Moreover they contribute to the mapping of viral hepatitis prevalence in a geographical area of Southern Europe and may be helpful in planning public health interventional strategies.
format Text
id pubmed-64645
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-646452002-01-23 Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study Koulentaki, Meri Ergazaki, Maria Moschandrea, Joanna Spanoudakis, Stelios Tzagarakis, Nikolaos Drandakis, Pandelis E Spandidos, Dimitrios A Kouroumalis, Elias A BMC Public Health Research Article BACKGROUND: So far the prevalence of viral hepatitis infection in hospitalized patients has not been extensively studied. Therefore we conducted the present five-year observational study to evaluate the prevalence of HBV and HCV infection in high-risk hospitalized patients of Crete, the largest Greek island, Due to the homogeneous population, epidemiological studies can be accurately done. METHODS: The study was carried out in two out of four District General Hospitals, and in the University Hospital of the island. Markers for HBV and HCV were studied and statistically evaluated according to age, sex and geographical area, in a well-defined hospitalized population. RESULTS: The total prevalence of HBsAg and anti-HCV in the three prefectures during the five-year study is 2.66% and 4.75% respectively. Overall the relative risks were higher in males than females for each hepatitis marker (p < 0.001). Higher prevalence of HBcAb was found in the 41–60 years age group for both sexes (males 36.17%, females 27.38%). Peak HBsAg prevalence was found in the age group of 21–40 and 41–60 years for males (5.4%) and females (3.09%) respectively. Anti-HCV prevalence increases with age reaching the highest prevalence in the age group of 41–60 years for males (7.19%) and in the 61–90 years age group for females (7.16%). For both sexes significant differences between the three locations were identified. For HBsAg a higher prevalence in Heraklion (3.96%) compared to Chania (2.30%, males: p < 0.0001, females: p < 0.05) and Rethymnon (1.45%, males: p < 0.01, females: p < 0.0001) was detected. For HCV a significantly higher prevalence in Heraklion (6.54%) compared to Chania (2.39%, males: p < 0.001, females: p < 0.001) but not in Rethymnon (5.15%, NS). A lower prevalence rate of HBcAb in Heraklion compared to Chania (20.07% versus 23.05%, males: p < 0.001, females: p < 0.001) was found. CONCLUSIONS: These results were possibly overestimated, but nevertheless reflect the situation of the general population within the island as shown by our previous publications in other study groups. Moreover they contribute to the mapping of viral hepatitis prevalence in a geographical area of Southern Europe and may be helpful in planning public health interventional strategies. BioMed Central 2001-12-21 /pmc/articles/PMC64645/ /pubmed/11806759 http://dx.doi.org/10.1186/1471-2458-1-17 Text en Copyright © 2001 Koulentaki et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Koulentaki, Meri
Ergazaki, Maria
Moschandrea, Joanna
Spanoudakis, Stelios
Tzagarakis, Nikolaos
Drandakis, Pandelis E
Spandidos, Dimitrios A
Kouroumalis, Elias A
Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title_full Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title_fullStr Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title_full_unstemmed Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title_short Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study
title_sort prevalence of hepatitis b and c markers in high-risk hospitalised patients in crete: a five-year observational study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64645/
https://www.ncbi.nlm.nih.gov/pubmed/11806759
http://dx.doi.org/10.1186/1471-2458-1-17
work_keys_str_mv AT koulentakimeri prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT ergazakimaria prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT moschandreajoanna prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT spanoudakisstelios prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT tzagarakisnikolaos prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT drandakispandelise prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT spandidosdimitriosa prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy
AT kouroumaliseliasa prevalenceofhepatitisbandcmarkersinhighriskhospitalisedpatientsincreteafiveyearobservationalstudy